Compare Domino's Pizza, Inc. (DPZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Neurocrine Biosciences Inc — how do they compare? Domino's Pizza, Inc. trades at $309.87 (market cap $10.21B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DPZ | NBIX | |
|---|---|---|
Market Cap | $10.21B | $14.36B |
Volume | 916,737 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $185.50 |
52-Week Low | $282.89 | $123.10 |
Typical Hold Time | 106 Days | 23 Days |
Enterprise Value | $15.17B | $14.37B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $303.10, showing minimal daily movement with a 0.08% gain. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while recent earnings misses and high debt levels of $5.7 billion create fundamental concerns. However, analyst sentiment remains positive with a $373 consensus price target representing 23% upside potential, supported by consistent revenue growth and strong profitability margins.
The outlook balances strong cash flow generation and market leadership against significant leverage and recent earnings disappointments. Investment opportunity exists in the valuation discount to analyst targets, but risks include debt servicing costs, competitive pressures, and execution challenges in maintaining growth momentum amid economic uncertainty.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
